Business
Oncology Pharma Appoints Dr. Vijay Mahant as the Chief Scientific Officer and Chief Operating Officer
Oncology Pharma Appoints Dr. Vijay Mahant as the Chief Scientific Officer and Chief Operating Officer.
About this update from Oncology Pharma Inc.
[{"type":"text","content":"\n San Francisco, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. is pleased to announce today that Vijay Mahant (M.S, Ph.D.) has been appointed as the Chief Scientific Officer (CSO) of Oncology Pharma and its Chief Operating Officer (COO).  Dr. Mahant is a scientist and an entrepreneur with about 35 years of experience in biotechnology.  He brings vast knowledge and experience in both R&D, business and management.  Mahant is a founder of MediLite Diagnostika, a former CSO and VP of R&D at Qualigen and a former executive VP of R&D at AutoGenomics.  Dr. Mahant has held senior R&D positions and management positions at Nichols Institute/Quest Diagnostics and Igen International.  He holds numerous international patents and he is on the Scientific Advisory Board of biotechnology companies such as Trutino Biosciences and Immunicom Inc. Chuck Wagner, President of Oncology Pharma, Inc., commented: ”Dr. Mahant has played an integral role as a Scientific Advisory Board member; he has put an outstanding scientific advisory team together for the company, licensed therapies and negotiated agreements.   I am very pleased to have such an outstanding individual join Oncology Pharma.” Dr. Mahant stated: \"The fight against cancer is a concerted global endeavor and it is most effective when it draws on multi-disciplines of science and medicine to push the frontiers of knowledge and practice, to tackle the challenges.  It is a pleasure and an honor for me to be the CSO and the COO, to contribute to the mission, vision and goals of Oncology Pharma.” ABOUT ONCOLOGY PHARMA, INC. ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the \"Company\") is a pioneering oncology company dedicated to developing, manufacturing, and commercializing therapeutics. The Company has licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. The Company is currently engaging in research and development of therapeutics for oncology, and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare. FORWARD LOOKING STATEMENTSCertain of the matters discussed in this announcement contain forward-looking stat...